• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Diabetes is one of the fastest growing diseases worldwide, projected to affect 693 million
adults by 2045. Devastating macrovascular complications (cardiovascular disease) and …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Background Renin–angiotensin system (RAS) inhibitors—including angiotensin-converting–
enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs)—slow the progression …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Executive summary 2020 will go down in history as the year when the global community was
awakened to the fragility of human health and the interdependence of the ecosystem …

Hypertension is the most common condition seen in primary care and leads to myocardial
infarction, stroke, renal failure, and death if not detected early and treated appropriately …

Diabetes mellitus is a complex, chronic illness requiring continuous medical care with
multifactorial risk reduction strategies beyond glycemic control. Ongoing patient self …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …